slides · global inventory
Consultants Gambit Problem Complication
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 5,737
Current window 4,861-4,890
Pages 192
Rows per page 30
Beat
4,861-4,890 of 5,737
05
The slide uses a combination of a data table and a bar chart to illustrate the trade-off between volume and profitability.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
06
The slide uses a color-coded table to contrast regional performance metrics.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
07
The chart uses a break in the y-axis to visualize the 43.6% to 44.2% change.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
08
The slide highlights improvements in margins and specific cost categories (Distribution, Warehouse, Other) following H1 initiatives.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
09
The slide uses a waterfall chart to bridge EBIT, specifically isolating the 'Driving Change' agenda items.Asos | Results Presentation Deck | 69 slides · Asos
Conference presentation Investor relations Beat · Problem & Complication1 hit
06
Deezer | Results Presentation Deck | 33 slidesDeezer | Results Presentation Deck | 33 slides · Deezer
Conference presentation Investor relations Beat · Problem & Complication1 hit
07
The slide uses a central heart motif to tie together four distinct strategic pillars.Deezer | Results Presentation Deck | 33 slides · Deezer
Conference presentation Investor relations Beat · Problem & Complication1 hit
06
Uses a 'From-To' framing to illustrate strategic evolution.D-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Problem & Complication1 hit
07
The slide uses a TRL (Technology Readiness Level) framework to position quantum annealers as market-ready compared to other quantum technologies.D-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Problem & Complication1 hit
08
Includes a testimonial from the CEO of Interpublic Group.D-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Problem & Complication1 hit
09
The chart uses a stacked area visualization to represent growing opportunity over time.D-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Problem & Complication1 hit
10
D-Wave | Investor Day Presentation Deck | 133 slidesD-Wave | Investor Day Presentation Deck | 133 slides · D-Wave
Conference presentation Investor relations Beat · Problem & Complication1 hit
07
The slide uses a table to contrast financial metrics and production strategies, positioning Eos as more efficient than competitors.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
The slide uses a three-pillar strategic framework to organize operational improvements.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
09
The slide uses a maturity model approach to show product evolution.Eos Energy | Investor Presentation Deck | 24 slides · Eos Energy Enterprises
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
06
Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
07
The slide uses a hub-and-spoke diagram to connect a central problem (CAR-T Neurotoxicity) to four specific negative outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
10
The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
13
The slide uses a hub-and-spoke diagram to highlight four key clinical outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
14
The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Problem & Complication1 hit
07
The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
Includes flow cytometry plots and bar charts showing efficacy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
The slide highlights both established houses and recent acquisitions (Valentino, Lindberg, Maui Jim, Creed).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Aha Moment1 hit
09
The slide uses a before-and-after comparison of strategic focus (pie charts) and provides a concrete implementation plan for 'Elevation strategy'.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Aha Moment1 hit
10
The slide uses a split-screen layout comparing Kering Eyewear (historical revenue growth) and Kering Beauté (timeline of launch and acquisition).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Aha Moment1 hit
13
The slide uses a grid-based layout to organize products by category, with each item labeled by name and price.Sonos | Results Presentation Deck | 34 slides · Sonos
Conference presentation Investor relations Beat · Problem & Complication1 hit